Project Summary
Strong epidemiological evidence linking cannabis use to depression and suicide suggests that the
endocannabinoid (eCB) system plays a key role in its pathophysiology. Understanding the neurobiology of
depression and suicide in young people is critically needed to identify new therapeutic targets for prevention
and treatment.
Fatty acid amide hydrolase (FAAH) is the enzyme responsible for the metabolism of eCBs such as
anandamide setting the tone of the eCB. In humans (periphery and postmortem) previous studies have
shown some evidence of altered eCB in depression. We present preliminary clinical data showing
relationships between FAAH and mood symptoms/guilt/resentment/impulsivity and aggression and trauma
(below age 6) and significant sex effects (higher FAAH in females). Preliminary postmortem data suggesting a
potential increase in FAAH protein expression in MDD who died by suicide (intermediate response in MDD) in
prefrontal Cortex (PFC), consistent with recent reports of reduction anandamide levels (likely high FAAH) in
suicide attempters. In addition, FAAH inhibition and the elevation of anandamide has been proposed as
treatment for depression/anxiety. Furthermore, anandamide can inhibit synaptic reuptake of neurotransmitters
implicated in depression. However, no study has investigated brain FAAH, the eCB gatekeeping enzyme,
in-vivo in brain in depression with and without suicide attempts, compared to healthy controls.
Our team has synthesized [11C]CURB and demonstrated its excellent properties for selective and reliable
PET brain imaging of FAAH (72). We also established the safety, validation and dosimetry of [11C]CURB
as well as its reproducible quantification (75, 76). Thus, the overall aim of our proposal is to use a novel and
validated radiotracer, [11C]CURB, to quantify the eCB rate limiting enzyme FAAH using Positron Emission
Tomography (PET) with a high-resolution research tomograph (HRRT) in young adults with current unipolar
(non-psychotic) major depression with a recent suicide attempt within the last 6 months with a lethality score of at
least 3 (D+SA), compared with similar age/sex matched depressed patients without life history of a suicide attempt
(D-SA) and age/sex matched Healthy Volunteers (HV). Our study will be the first to investigate the contribution of
the eCB (FAAH) in depression and suicidal behaviors, perhaps usable as a novel molecular target amenable for
more physiological intervention (i.e. FAAH) to regulate eCB in depression and suicide.
The PI and her colleagues have a considerable track record of performing complex molecular PET imaging
studies in vulnerable youth (34, 73-82). The high-resolution PET scanner, well characterized radiotracer
and the infrastructure for neurobiological research in depression and suicide are novel aspects of the
project that will provide a fundamental basis for future studies of pharmacologic interventions in depression
and suicidal behavior focused on the eCB.